As can be seen in the Figure, the most frequent adverse reactions pertaining to dabigatran in the RE-LY trial were GI events, with about a 5% higher incidence of discontinuation due to GI reactions with dabigatran than with warfarin, and with about 20% of subjects experiencing GERD-like symptoms with dabigatran (not shown).[96]